Novavax Vaccine effective against UK corona variants
Novavax shares recorded a 34% increase. It was reported that this speeding was seen after the release of the results of its first case of a South African version in the US after releasing the test results.
New Delhi: Novavax Inc. said that its corona virus vaccine was effective at up to 89.3% to prevent COVID-19 in a test conducted in the United Kingdom on Thursday. According to preliminary analysis, to be nearly as effective at protecting from the most highly infectious variants ever discovered in Britain found.
At the same time, a mid-stage trial of the vaccine in South Africa, where the new virus version became a major problem, saw 60% effectiveness in people who did not have HIV.
Novavax is highly effective:
Novavax shares recorded a 34% increase. It was reported that this speeding was seen after the release of the results of its first case of a South African version in the US after releasing the test results. Novavax is already stocking the vaccine at six operating manufacturing locations and was told that it is expecting a total of eight plants from seven countries, which will be able to produce 2 billion doses per year, including Serum Institute of India also includes.
It was reported that the UK trial, which has enrolled 15,000 people between the ages of 18 and 84. It will be applied for use in the UK, EU and other countries. Approval of the Novavax vaccine will be most welcome in Europe. As it is in a conflict situation over Pfizer / BioNotech and AstraZeneca PLC receiving fewer vaccines than expected.
Pune-based Serum Institute has tied up with pharmaceutical company Novavax Inc. to produce its potential corona vaccine for India and other countries. According to the agreement, the Serum Institute will produce two billion doses of Novavax every year. Serum has also tied up with US company Kodagenics to produce and distribute its Corona vaccine.